10-K/A: AirSculpt Technologies Files 10-K/A to Correct EBITDA

AirSculpt Technologies, Inc. filed an amendment to its 2025 Annual Report to correct non-GAAP financial measure errors related to its London facility closure.

Summary

• The company filed an amendment (Form 10-K/A) to its 2025 Annual Report to correct errors in non-GAAP financial measures.
• The errors involved an inaccurate one-time non-cash adjustment related to the closure of the London facility.
• Adjusted EBITDA and Adjusted Net Income were overstated by approximately $2.6 million and $2.7 million, respectively, for the year ended December 31, 2025.
• The errors did not impact the company's consolidated financial statements prepared in accordance with GAAP.
• The company confirmed these errors do not indicate additional material weaknesses in internal control over financial reporting beyond those previously disclosed.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the combination of declining financial performance, a material weakness in internal controls, and the need to restate financial disclosures.

Positives

• The errors were limited to non-GAAP financial measures and did not impact the company's GAAP-compliant consolidated financial statements.
• The company has taken corrective action by filing this amendment and updating required certifications.
• The company maintains a 100% private pay model, eliminating reimbursement risk.

Negatives

• Revenue for the year ended December 31, 2025, was $151.8 million, a 15.8% decline compared to $180.4 million in 2024.
• The company reported a net loss of $11.7 million for 2025, compared to a net loss of $8.0 million in 2024.
• Management identified a material weakness in internal control over financial reporting related to general accounting processes and lease accounting.
• The company closed its London facility due to poor financial performance.

Risks

• Inability to successfully implement cost-savings initiatives and revenue growth strategies.
• Increased competition in the weight loss and obesity solutions market, particularly from weight-loss drugs.
• Dependence on a single third-party manufacturer (Euromi) for key surgical handpieces.
• Exposure to variable interest rate risk on debt.
• Potential for future litigation or regulatory actions regarding corporate practice of medicine and fee-splitting laws.

Future Outlook

The company intends to focus on returning to revenue growth through strategic initiatives, including optimizing marketing investments, strengthening sales execution, expanding consumer financing options, and introducing new product lines, while pausing new center openings in the near term to improve liquidity.

Management Comments

• Management concluded that the non-GAAP presentation errors do not reflect the identification of any additional material weaknesses in internal control over financial reporting previously disclosed.
• Management believes that by restoring same-store revenue growth through optimized marketing investments, stronger sales execution, expanded consumer financing options, and the introduction of new product lines, it can improve unit-level economics.

Industry Context

StockSavvy.ai notes that the aesthetic surgery industry is currently facing headwinds from the rapid adoption of GLP-1 weight-loss drugs, which is impacting demand for traditional body contouring procedures. AirSculpt's revenue decline reflects these broader market pressures.

Comparison to Industry Standards

• The company operates in a highly competitive market against traditional liposuction providers, medical spas, and non-surgical weight loss solutions.
• The company's 100% private pay model is a differentiator compared to medical practices reliant on insurance reimbursement.
• The company's unit-level economics are described as highly attractive, with centers typically achieving profitability within three months.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in ordinary course legal actions, including medical malpractice claims, which management believes will not have a material adverse effect on the company.

Related Party Transactions

• The company has agreements with its private equity sponsor, Vesey Street Capital Partners, L.L.C., including a Limited Guarantee related to the Credit Agreement.

Stakeholder Impact

• Shareholders may be impacted by the volatility of the stock price and the dilution from equity offerings.
• Creditors are impacted by the company's leverage and the need to maintain compliance with financial covenants.

Next Steps

• Continue remediation efforts for identified material weaknesses in internal control over financial reporting.
• Execute cost-savings initiatives and revenue growth strategies.
• Hold the 2026 Annual Meeting of Stockholders on May 12, 2026.

Key Dates

Recommendation

The combination of declining revenue, widening net losses, and identified material weaknesses in internal controls presents significant operational and financial risks that outweigh the potential for a turnaround in the near term.

Keywords

AirSculpt, body contouring, aesthetic surgery, 10-K/A, financial restatement, non-GAAP, AIRS